Paychex price target raised to $153 from $150 at TD Cowen

TD Cowen raised its Paychex (PAYX) price target to $153 from $150 with a Hold rating, anticipating Q4 results slightly above expectations due to stable demand and strong financial health. The firm expects solid execution from Paychex, but notes potential "deal noise" compared to consensus estimates, which it views as stale. Paychex recently completed its $4.1 billion acquisition of Paycor (PYCR), expected to yield over $80 million in annual cost synergies by fiscal 2026 and be accretive to adjusted EPS in the same year; the company also announced a 10% dividend increase.

Analysis

TD Cowen has revised its price target for Paychex (NASDAQ:PAYX) upwards to $153.00 from $150.00, while reiterating a Hold rating prior to the company's Q4 earnings report on June 25. This adjustment reflects anticipation that Paychex will report results slightly exceeding Wall Street expectations, supported by a stable demand and employment landscape, alongside the company's robust 72% gross profit margin and strong financial health metrics noted by InvestingPro. Despite these positive indicators, InvestingPro analysis suggests Paychex, currently trading at $154.38 with a market capitalization of $55.6 billion, is positioned above its Fair Value. TD Cowen highlights potential "deal noise" in Q4 results relative to consensus estimates, which it deems "largely stale" due to lacking contribution from Paylocity (NASDAQ:PCTY) (PYCR). Consequently, TD Cowen has marginally increased its fiscal 2026 and 2027 earnings per share estimates for Paychex, attributing this to benefits from changes in the deferred contract costs amortization period related to Paylocity. The new $153 price target is predicated on a 27.5x price-to-earnings multiple applied to calendar year 2026 estimated earnings.

Strategically, Paychex has completed its acquisition of Paycor (NASDAQ:PYCR) for approximately $4.1 billion. This transaction is poised to bolster Paychex's technological and service offerings, with management projecting annual cost synergies surpassing $80 million by fiscal 2026 and expecting the merger to be accretive to adjusted diluted earnings per share within the same fiscal year. Reinforcing its commitment to shareholder returns, Paychex also announced a 10% increase in its quarterly cash dividend to $1.08 per share. Other analysts offer varied perspectives: RBC Capital maintains a $165 price target, citing stable employment levels, positive small business sentiment, and potential tailwinds from higher interest rates. Morgan Stanley reiterated an Equalweight rating with a $150 price target, adjusting its earnings forecasts to incorporate the Paycor acquisition, which it views as a catalyst for expanding Paychex's total addressable market and enhancing cross-selling opportunities. A significant governance change is also on the horizon, with founder B. Thomas Golisano announcing his retirement from the board of directors effective July 2025.

Key Decisions for Investors

• Investors should acknowledge the positive operational outlook, including an anticipated earnings beat and a 10% dividend increase, but weigh these against Paychex's current valuation, which InvestingPro suggests is above Fair Value, and the prevailing Hold/Neutral ratings from analysts like TD Cowen and Morgan Stanley.
• Closely monitor Paychex's Q4 earnings report on June 25 for confirmation of financial performance, detailed insights into the integration of the $4.1 billion Paycor acquisition, progress on achieving the projected $80 million in synergies, and management's commentary on the "deal noise" relative to consensus expectations.
• Assess the long-term strategic implications of the Paycor acquisition for market share and growth, alongside the potential impact of founder B. Thomas Golisano's upcoming retirement in July 2025 on company leadership and direction.
• Consider TD Cowen's valuation metric of a 27.5x P/E multiple on calendar year 2026 earnings for its $153 price target as a benchmark when evaluating the stock's risk-reward profile, especially given its recent share price outperformance.